Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
Posted inClinical Trials CVS Caremark Corporation Drugs (Pharmaceuticals) Eli Lilly and Company GLP-1 RAs (Drug) Health Insurance and Managed Care Novo Nordisk A/S Obesity Prices (Fares, Fees and Rates) Research Weight

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats
Posted inDrugs (Pharmaceuticals) Eli Lilly and Company Food and Drug Administration GLP-1 RAs (Drug) Hims & Hers Health Inc Jorgensen, Lars Fruergaard Makary, Marty Novo Nordisk A/S Obesity Prices (Fares, Fees and Rates) Shortages Telemedicine Weight

Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
Posted inDrugs (Pharmaceuticals) GLP-1 RAs (Drug) Health and Human Services Department Health Insurance and Managed Care Medicare Novo Nordisk A/S Obesity Ozempic (Drug) Prices (Fares, Fees and Rates) United States Politics and Government Weight

Medicare to Negotiate Lower Prices for Weight-Loss Drugs

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.